Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
BioMed Research International 2015:648108
Contraindications: - Personal or family history of medullary thyroid carcinoma (MTC) - Multiple Endocrine Neoplasia syndrome type 2 (MEN2) - Serious hypersensitivity to orforglipron Safety profile: Common adverse effects include nausea, diarrhea, constipation, vomiting, abdominal pain, and fatigue
In the TRIUMPH-4 Phase 3 trial, the most common adverse events for the 12 mg dose were nausea (43.2%), diarrhea (33.1%), constipation (25.0%), vomiting (20.9%), and decreased appetite
Septernas preclinical data showed that combining its oral GIP receptor agonist with semaglutide produced tirzepatide-like weight loss in mice
US$ 28.66
US$ 29.73
US$ 22.65
US$ 29.14
US$ 27.34
US$ 21.53
US$ 24.56
